EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis

Aisling McGuigan, Hannah A Blair

CNS Drugs · 2026-11 · 40 (11) · 1547-1559

DOI: 10.1007/s40263-026-01335-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 30.09.2026. Verfasst von Aisling McGuigan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Cholinergic, Receptor Protein-Tyrosine Kinases, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO®), a humanised immunoglobulin G4P monoclonal antibody, is a subcutaneously administered neonatal Fc receptor (FcRn) inhibitor approved for the treatment of both acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) autoantibody-positive (Ab+) generalised myasthenia gravis (gMG) in adults. The pivotal, randomised, placebo-controlled phase III MycarinG trial demonstrated that a 6-week cycle of once-weekly rozanolixizumab ≈ 7 mg/kg or ≈ 10 mg/kg resulted in statistically significant and clinically meaningful improvements across all myasthenia gravis-specific scales assessed at day 43 versus placebo. Treatment benefits were rapid, sustained and consistent across repeated symptom-driven rozanolixizumab cycles. In a randomised, open-label, phase III crossover trial, self-administered rozanolixizumab improved MG symptoms regardless of whether manual push or infusion pump method was used. Rozanolixizumab was generally well tolerated with an acceptable safety profile; the most common adverse events were headache, diarrhoea, pyrexia and nausea. Thus, rozanolixizumab is an efficacious and generally well tolerated therapy for adults with AChR or MuSK Ab+ gMG, representing a convenient and valuable additional treatment option for these patients. Generalised myasthenia gravis (gMG) is a lifelong autoimmune disorder in which harmful immunoglobulin G (IgG) antibodies interfere with signalling between nerves and muscles, causing muscle weakness and fatigue. These antibodies most often target the acetylcholine receptor (AChR) or, less commonly, muscle-specific kinase (MuSK). gMG can affect the muscles of the eyes, head, neck and limbs and, in some cases, those used for breathing, talking and swallowing, which can lead to serious complications. As there is currently no cure for gMG, treatments aim to improve symptoms and quality of life by controlling the immune system. Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO®), a monoclonal antibody, blocks the neonatal Fc receptor (FcRn) that plays a key role in the persistence of IgG, thereby reducing the amount of IgG in the body. Once-weekly subcutaneous rozanolixizumab for 6 weeks improved gMG symptoms and daily functioning more than placebo in adults, and repeated treatment cycles showed ongoing benefit. Moreover, many patients were able to successfully self-administer rozanolixizumab by syringe or infusion pump, with similar treatment benefits. Rozanolixizumab was generally well tolerated; the most common adverse events were headache, diarrhoea, fever and nausea. Thus, rozanolixizumab is an efficacious and generally well tolerated therapy for adults with AChR or MuSK autoantibody-positive gMG, representing a convenient and valuable additional treatment option for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisReceptors, CholinergicReceptor Protein-Tyrosine KinasesAntibodies, Monoclonal, HumanizedAutoantibodiesHumansAnimalsRandomized Controlled Trials as Topic

Substanzen

Receptors, CholinergicReceptor Protein-Tyrosine KinasesAntibodies, Monoclonal, HumanizedrozanolixizumabAutoantibodiesMUSK protein, human

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Zitieren

APA

McGuigan, A., & Blair, H. A. (2026). Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis. CNS Drugs, 40(11), 1547-1559. https://doi.org/10.1007/s40263-026-01335-3

Vancouver

McGuigan A, Blair HA. Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis. CNS Drugs. 2026;40(11):1547-1559. doi:10.1007/s40263-026-01335-3

BibTeX
@article{McGuigan2026,
  author = {McGuigan, Aisling and Blair, Hannah A},
  title = {Rozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis},
  journal = {CNS Drugs},
  year = {2026},
  volume = {40},
  number = {11},
  pages = {1547--1559},
  doi = {10.1007/s40263-026-01335-3}
}
Kostenlos starten →